GRI BIO INC (GRI) Stock Price & Overview
NASDAQ:GRI • US3622AW5029
The current stock price of GRI is 2.4 USD. Today GRI is down by 0%. In the past month the price decreased by -9.09%. In the past year, price decreased by -98.69%.
GRI Key Statistics
- Market Cap
- 3.48M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -194.93
- Dividend Yield
- N/A
GRI Stock Performance
GRI Stock Chart
GRI Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to GRI. When comparing the yearly performance of all stocks, GRI is a bad performer in the overall market: 99.8% of all stocks are doing better.
GRI Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to GRI. GRI scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
GRI Earnings
GRI Forecast & Estimates
6 analysts have analysed GRI and the average price target is 656.88 USD. This implies a price increase of 27270% is expected in the next year compared to the current price of 2.4.
GRI Groups
Sector & Classification
GRI Financial Highlights
Over the last trailing twelve months GRI reported a non-GAAP Earnings per Share(EPS) of -194.93. The EPS increased by 95.65% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -137.96% | ||
| ROE | -199% | ||
| Debt/Equity | 0 |
GRI Ownership
GRI Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 16 | 417.437B | ||
| AMGN | AMGEN INC | 16.31 | 204.229B | ||
| GILD | GILEAD SCIENCES INC | 16.27 | 183.894B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.6 | 121.25B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.47 | 83.255B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 47.84 | 43.24B | ||
| INSM | INSMED INC | N/A | 31.965B | ||
| NTRA | NATERA INC | N/A | 28.775B | ||
| BIIB | BIOGEN INC | 12.36 | 27.876B | ||
| MRNA | MODERNA INC | N/A | 22.581B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.24 | 21.486B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 20.053B | ||
| EXAS | EXACT SCIENCES CORP | 308.82 | 19.749B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find more ETFs on the USA exchanges | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About GRI
Company Profile
GRI Bio Inc is a US-based company operating in Biotechnology industry. The company is headquartered in La Jolla, California and currently employs 4 full-time employees. The company went IPO on 2021-02-10. GRI Bio, Inc. is a clinical-stage biopharmaceutical company focused on fundamentally changing the way inflammatory, fibrotic and autoimmune diseases are treated. The Company’s therapies are designed to target the activity of Natural Killer T (NKT) cells, which are key regulators earlier in the inflammatory cascade, to interrupt disease progression and restore the immune system to homeostasis. Its lead program, GRI-0621, is an inhibitor of iNKT cell activity and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis. The firm is also developing a pipeline of novel type II diverse NKT agonists for the treatment of systemic lupus erythematosus. Its product candidate portfolio also includes GRI-0803 and a proprietary library of more than 500 compounds. The company is developing GRI-0803 for the treatment of autoimmune disorders, with much of its preclinical work in systemic lupus erythematosus disease (SLE) and multiple sclerosis (MS).
Company Info
GRI BIO INC
2223 Avenida De La Playa, Suite 208
La Jolla CALIFORNIA US
Employees: 4
Phone: 16194001171
GRI BIO INC / GRI FAQ
What does GRI BIO INC do?
GRI Bio Inc is a US-based company operating in Biotechnology industry. The company is headquartered in La Jolla, California and currently employs 4 full-time employees. The company went IPO on 2021-02-10. GRI Bio, Inc. is a clinical-stage biopharmaceutical company focused on fundamentally changing the way inflammatory, fibrotic and autoimmune diseases are treated. The Company’s therapies are designed to target the activity of Natural Killer T (NKT) cells, which are key regulators earlier in the inflammatory cascade, to interrupt disease progression and restore the immune system to homeostasis. Its lead program, GRI-0621, is an inhibitor of iNKT cell activity and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis. The firm is also developing a pipeline of novel type II diverse NKT agonists for the treatment of systemic lupus erythematosus. Its product candidate portfolio also includes GRI-0803 and a proprietary library of more than 500 compounds. The company is developing GRI-0803 for the treatment of autoimmune disorders, with much of its preclinical work in systemic lupus erythematosus disease (SLE) and multiple sclerosis (MS).
What is the stock price of GRI BIO INC today?
The current stock price of GRI is 2.4 USD.
What is the dividend status of GRI BIO INC?
GRI does not pay a dividend.
How is the ChartMill rating for GRI BIO INC?
GRI has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the GICS sector and industry of GRI stock?
GRI BIO INC (GRI) operates in the Health Care sector and the Biotechnology industry.
What is the next earnings date for GRI stock?
GRI BIO INC (GRI) will report earnings on 2026-05-13.